The E2F family of transcription factors regulates the expression of a number of genes whose products are involved in cell cycle control, DNA replication and apoptosis. We show here that E2F-1 binds in vivo the promoters of ASPP1 and ASPP2 genes, two activators of p53-mediated apoptosis, E2F-1, E2F-2 and E2F-3 all activate the isolated ASPP1 and ASPP2 promoters. Overexpression or deregulation of E2F-1 increased the expression levels of ASPP1 and ASPP2 mRNA and proteins. The identification of ASPP1 and ASPP2 genes as transcriptional targets of E2F provides another mechanism by which E2F cooperates with p53 to induce apoptosis.
Introduction
Mutated in more than half of human cancers, 1 p53 remains one of the most important tumour suppressors identified so far. In response to multiple environmental stresses, p53 is rapidly activated and it functions in inhibiting cell growth either by the induction of cell cycle arrest or apoptosis. However, the tumour suppressor function of p53 is perhaps best linked to its ability to induce apoptosis. [2] [3] [4] Interestingly, the activation of p53 in normal cells usually results in cell cycle arrest, whereas in transformed cells it often induces cell death. 5 This provides an ideal base to specifically kill wild-type (wt) p53 expressing tumour cells. However, the precise determinants for the sensitivity of tumour cells to p53-induced apoptosis are not yet fully understood.
Tumorigenesis in many cell types involves the inactivation of the retinoblastoma (Rb) pathway. One of the primary consequences of Rb inactivation is the deregulated activity of E2F. The E2F family of transcription factors plays a central role in regulating cellular proliferation by promoting the expression of genes required for cell cycle progression. Importantly, in addition to inducing proliferation, deregulated E2F activity can also trigger apoptosis via both p53-dependent and -independent pathways. [6] [7] [8] Therefore, it is possible that part of the apoptotic sensitivity of tumour cells is due to the ability of E2F-1 to stimulate the apoptotic function of p53. One molecular mechanism that has been associated with E2F-induced p53 dependent apoptosis involves the induction of the ARF tumour suppressor gene by E2F. 9 ARF interacts with Mdm2 and inhibits its ability to target p53 for ubiquitination and subsequent degradation. 10 However, results from studies of mutant mouse models indicate that E2F can induce p53-dependent apoptosis in the absence of ARF. 11, 12 Although this does not rule out a role for ARF in the E2F-mediated activation of p53, it suggests the existence of ARF-independent pathways in mediating apoptosis induced by E2F and p53.
The discovery of the apoptosis-stimulating proteins of p53 (ASPP) family of proteins revealed a key mechanism through which the apoptotic function of p53 is regulated. 13, 14 The ASPP family consists of three members, ASPP1, ASPP2 and iASPP, and they all bind p53 via their C-terminus. ASPP1 and ASPP2 stimulate, whereas iASPP inhibits, the apoptotic function of p53 and its family members, p63 and p73, 15 both in vitro and in vivo. The importance of the ASPP/p53 regulation is reflected by the observation that Caenorhabditis elegans iASPP and human iASPP are interchangeable.
14 The human ASPP family members also regulate the apoptotic function of C. elegans p53 in a similar way as that of human p53. 14 We thus investigated whether E2F can cooperate with p53 to induce apoptosis by regulating the expression of the ASPP family of proteins, since an increased expression of ASPP2 in response to E2F-1 activation was previously reported in a gene array study. 16 
Results

ASPP1 and ASPP2 promoters contain putative E2F binding sites
To understand how the expression of the ASPP1 and ASPP2 genes are regulated in vivo, promoters of ASPP1 (À736 to þ 96) and ASPP2 (À323 to þ 217) were isolated from genomic DNA and scanned for the presence of theoretical E2F binding sites using the method described by Kel et al.
17
(and Materials and Methods). By means of this software, we were able to identify potential E2F binding sites both on the promoters of ASPP1 (four sites) and ASPP2 (two sites) ( Figure 1 ). These findings suggested that ASPP1 and ASPP2 might be potential transcriptional targets of E2F.
E2F-1 binds ASPP1 and ASPP2 promoters in vivo
To determine whether E2F-1 binds to the promoter regions of ASPP1 and ASPP2 genes, we performed a chromatin immunoprecipitation assay (ChIP) in Saos-2 cells inducible for the expression of wt E2F-1. 18 As shown in Figure 2a , over 80% of the cells expressed inducible E2F-1 at high levels in comparison to the uninduced cells. Anti-E2F-1 antibody C-20 was used to immunoprecipitate formaldehyde crosslinked E2F-1-DNA complexes derived from Saos-2 cells expressing endogenous or overexpressed E2F-1. The presence of ASPP1 and ASPP2 promoter sequences in the immunoprecipitates was verified by PCR using primers surrounding the identified putative E2F binding sites within the ASPP1 and ASPP2 promoters. As shown in Figure 2b , ASPP1 and ASPP2 promoter sequences were specifically detected in the immunoprecipitates derived from E2F-1 antibody but not from the negative control rabbit immunoglobulin, suggesting that endogenous E2F-1 binds ASPP1 and ASPP2 promoters in vivo. Consistent with this, increased amounts of ASPP1 and ASPP2 promoter sequences were also detected in cells expressing inducible E2F-1 (Figure 2b) . These results provided a strong positive confirmation for the functional significance of the predicted E2F binding sites within the ASPP1 and ASPP2 promoters and suggested that ASPP1 and ASPP2 may be novel targets of E2F-1 in vivo.
E2F-1 transactivates the promoters of ASPP1 and ASPP2
To investigate whether E2F-1 could activate the isolated ASPP1 and ASPP2 promoters, the ASPP1 and ASPP2 promoter fragments containing the putative E2F binding sites were cloned into a luciferase reporter plasmid. The responsiveness of these promoters to E2F-1 was then tested in Saos-2 cells. Increasing amounts of E2F-1 stimulated the activity of both ASPP1 and ASPP2 promoters (Figure 3a) . At the highest concentration, the extent of activation on the ASPP1 promoter by E2F-1 was almost comparable to a wellknown artificial promoter containing three E2F binding sites (3 Â wt-luc (luciferase reporter gene)). Interestingly, the responsiveness of the ASPP2 promoter to E2F-1 was much higher than that of 3 Â wt-luc (Figure 3a) . The transactivation function of E2F-1 was required to stimulate the transcriptional activity of ASPP1 and ASPP2 promoters since a transcriptionally defective E2F-1 mutant, E2F-1(1-400), did not effect the promoter activity of ASPP1 and ASPP2 (Figure 3b) .
We focused our studies on the identification of the critical E2F binding site within the ASPP1 promoter since the ASPP1 and ASPP2 are transcriptional targets of E2F-1, E2F-2 and E2F-3
While some reports recognise E2F-1 as the only member of the family capable of promoting apoptosis, [19] [20] [21] other studies have shown high levels of cell death in cells expressing active E2F-1, E2F-2 or E2F-3. 22 It was therefore important to investigate whether ASPP1 and ASPP2 are specific targets of E2F-1 or their transactivation is a property shared by all three E2F. Expression plasmids of E2F-1, E2F-2 and E2F-3 were first titrated to obtain the expression level that activated the control 3 Â wt-luc reporter with similar efficiency. Under these conditions, the expression of E2F-1, E2F-2 and E2F-3 led to comparable increases in ASPP2 promoter activity (Figure 4 ), suggesting that all three E2F transcriptional activators can efficiently stimulate the activity of the ASPP2 promoter. Similarly, the promoter activity of ASPP1 was also induced by the expression of E2F-1, E2F-2 and E2F-3.
Increased expression of E2F-1 upregulates endogenous ASPP1 and ASPP2 mRNA and protein levels
To demonstrate that E2F-1 induces the expression of endogenous ASPP1 and ASPP2, total RNA was extracted from Saos-2 and H1299 cells inducible for the expression of E2F-1. RT-PCR was then performed to detect the expression levels of ASPP1 and ASPP2 mRNA. The induced expression of E2F-1 resulted in a significant increase in ASPP1 and ASPP2 mRNA and protein levels in Saos-2 cells (Figure 5a ). Similar results were also obtained in H1299 cells (Figure 5b) . Furthermore, the transcriptional activity of E2F-1 is required to induce the expression of ASPP1 and ASPP2 since the transcriptional defective E2F-1 mutant, E2F-1 (1-400), failed to induce the expression of ASPP1 and ASPP2 (Figure 5c ). These data indicated that ASPP1 and ASPP2 are transcriptional targets of E2F-1 in vivo.
Endogenous E2F can elevate the expression of ASPP1 and ASPP2
To provide evidence that ASPP1 and ASPP2 are regulated by endogenous E2F, Saos-2 cells were cultured for 48 h in medium supplemented with 0.1 or 20% serum to obtain arresting or cycling cells (Figure 6a -182/ +19 . By binding to the Rb protein, oncogenes like E1A dissociate Rb/E2F complexes leading to the deregulation of endogenous E2F activity. The expression levels of endogenous ASPP1 and ASPP2 were measured in human retina pigment epithelial cells (RPE) expressing either a control vector or E1A. An increased expression of a known E2F target gene, p73, 23, 24 was detected in the E1A expressing RPE cells but not in the control cells. Similarly, the expression of E1A also induced the expression of ASPP1. Interestingly, however, under the same conditions, the presence of E1A had much less effect on the expression levels of ASPP2 (Figure 6b ). These results suggest that elevated E2F activity is sufficient to increase the expression of ASPP1 and ASPP2 in vivo.
Discussion
Existing studies showed that E2F cooperates with p53 to induce apoptosis in vitro and in vivo. There are many pathways through which E2F can increase p53-mediated apoptosis. E2F-1, E2F-2 and E2F-3 can increase the apoptotic function of p53 through protein-protein interaction. 25 By transactivating p14Arf (p19Arf in mouse), E2F can also increase the expression levels of p53 since Arf binds Mdm2 and prevents Mdm2-mediated degradation of p53. Additionally, E2F and p53 can also transactivate common target genes like Apaf-1, 26, 27 PUMA and Noxa, 28 and therefore cooperate in the induction of apoptosis. The identification of ASPP1 and ASPP2 as transcriptional targets of E2F provides another pathway by which E2F increases the apoptotic function of p53, since ASPP1 and ASPP2 are specific activators of p53-mediated apoptosis. 13 In addition, ASPP1 and ASPP2 are also activators of p63 and p73. 15 Thus, E2F may use this pathway to increase the apoptotic function of p63 and p73 independently of p53.
Using a recently described computer-assisted tool for the identification of potential E2F binding sites, 17 we identified putative E2F binding sites within ASPP1 and ASPP2 promoter sequences (4 and 2, respectively). ChIP experiments allowed us to demonstrate that endogenous and exogenous E2F-1 can bind both ASPP1 and ASPP2 promoter sequences in vivo. Consequently, increased expression of E2F-1 also induced the expression of ASPP1 and ASPP2 at both mRNA and protein levels. Based on the truncation studies of the ASPP1 promoter, we hypothesised that the E2F binding site located within the untranscribed region of exon 1 might be the main E2F-responsive site since the most responsive fragment of ASPP1 contains only this site. Further studies are required to test this hypothesis, especially in light of the ASPP2 promoter analysis performed by Chen et al. in the accompanying paper, which indicates a complex regulation of the transcriptional activity of the ASPP2 promoter by E2F.
Nevertheless, the results shown here demonstrate that ASPP1 and ASPP2 are novel transcriptional targets of E2F. Inactivation of Rb pathways is one of the most common defects found in human cancers. Therefore, most of the tumour cells will have increased E2F activity and consequently an increased expression of ASPP1, ASPP2 or both. In agreement with this, increased expression of ASPP1 was detected in RPE cells expressing the E1A oncogene, which is known to prevent Rb from inhibiting the transcriptional activity of E2F. Importantly, E1A was previously shown to sensitise mouse primary fibroblast cells to p53-mediated apoptosis. 29 Perhaps increased expression of ASPP1 or ASPP2 is one of the underlining mechanisms by which E1A enhances the cellular sensitivity to p53-mediated apoptosis. Similar mechanisms may also explain at least in part why most tumour cells are more sensitive to p53-mediated apoptosis than their normal counterparts. 
Materials and Methods
Cloning of the ASPP1 and ASPP2 promoters and plasmids
The ASPP1 and ASPP2 promoters were amplified from human genomic DNA using primers specific for ASPP1 or ASPP2 sequences listened below. The fragments were cloned into pCDNA-3.1-His-V5-TOPO (Invitrogen) and later excised by digestion and subcloned into pGL3-Basic (Promega). The resulting constructs comprise the À736 to þ 96 promoter region of ASPP1 and the À323 to þ 217 promoter region of ASPP2 (measured relative to the longest 5 0 EST currently available, GeneBank gi 21848243 and gi 30774493 for ASPP1 and ASPP2, respectively).
Identification of putative E2F binding sites within ASPP1 and ASPP2 promoters
The ASPP1 and ASPP2 promoters were scanned for likely E2F response elements by means of the SiteScan search algorithm (http://compel.bionet.nsc.ru/FunSite/SiteScan.html) as described in Kel et al. 17 By using this software, we identified two E2F binding sites on the ASPP2 promoter using the weight matrix with score of context option and a q parameter of 0.8 and four E2F binding sites on the ASPP1 promoter using the plain weight matrix method and a q value of 0.81.
Cell culture, antibodies and plasmids
Saos-2, H1299 and RPE cells were grown in DMEM supplemented with 10% foetal calf serum (FCS). Full-length E2F-1 cDNA and E2F-1(1-400) were cloned into the pcDNA-3 expression plasmid (Invitrogen) in frame with the 9E10 epitope tag at the N-terminus. The 9E10 epitope was recognised by the mouse monoclonal antibody 9E10. The mouse monoclonal antibody PC-10 is specific to the proliferating cell nuclear antigen (PCNA) protein. C-20, an anti-E2F-1 polyclonal antibody used in the immunoprecipitation assays, was purchased from Santa Cruz Biotechnology. Expression plasmids used in this study were driven by the CMV immediate-early promoter.
E2F-1 inducible H1299 and Saos-2 cell lines
Saos-2 cells expressing inducible E2F-1 under the pTET-On system were described previously. 18 In H1299 cells, E2F-1 expression was controlled under ponasterone A. This cell line was constructed according to the manufacturer's specifications (Invitrogen, USA).
ChIP assay
Cells were crosslinked with 1% formaldehyde (Fisher Scientific) in PBS for 10 min at room temperature. The crosslinking reaction was stopped by adding glycine to a final concentration of 0.125 M. Crosslinked cells were washed twice with cold PBS, trypsinised, washed with PBS and lysed in 500 ml of RIPA buffer 30 containing a protease inhibitor cocktail (Complete Mini, Roche), NaF (50 mM), Na 3 VO 4 (1 mM) and b-glycerophosphate (10 mM). Samples were sonicated with a Heat Systems sonicator (six bursts of 15 s each) on ice, and centrifuged at 20 000 Â g for 10 min. Samples (2-4 mg) of protein extracts were precleared with 10 ml of Protein E2F-1 inducible cell lines were treated with doxycycline (2 mg/ml) and ponasterone A (10 mM), respectively, for the indicated hours to induce the expression of E2F-1. Antibodies C-20, mASPP1/54.2 and mASPP2/ 54.10 were used to detect the expression of E2F-1, ASPP1 and ASPP2, respectively (first four panels). PCNA was used as a loading control. RT-PCR was performed using total RNA extracted from cells at the indicated hours after the induction of E2F-1. Primers specific to ASPP1 or ASPP2 were used to amplify ASPP1 or ASPP2 cDNA. The expression of GAPDH gene was used to ensure that equal amounts of total cDNA were used for each time point. Basal levels of ASPP1 and ASPP2 mRNA and proteins were detected in uninduced cells (À). The transcription defective E2F-1 (1-400) failed to induce the expression of ASPP1 and ASPP2 mRNA in Saos-2 cells (c)
E2Fs regulate the expression of ASPP genes V Fogal et al G Sepharose beads (preblocked with 1 mg/ml BSA and 1 mg/ml salmon sperm DNA) for 2 h at 41C and immunoprecipitated overnight at 41C with 2 mg of anti E2F-1 C-20 antibody. Rabbit IgG (2 mg) were used as negative control for the immunoprecipitation. Immunoprecipitates were washed twice with RIPA buffer, four times with IP washing buffer, 30 twice with RIPA buffer and twice with 1 Â TE. In all, 20% of the supernatant from the rabbit IgG immunoprecipitation was saved as total input of chromatin, and was processed with the eluted immunoprecipitates beginning at the crosslink reversal step. Immunocomplexes were eluted for 10 min at 851C in 125 ml of 1% SDS/100 mM NaHCO 3 . A total of 0.1 mg/ml of salmon sperm DNA and 10 mg of RNAse A were add to the pooled eluates and crosslinks were reverted by incubation for 6 h at 651C. Samples were diluted with 125 ml of water containing 0.16 mg/ml proteinase K, and incubated for 1 h at 501C. DNA was purified with phenol/chloroform and a fraction was used as PCR template to detect the presence of the promoter sequences of ASPP1 or ASPP2 (30 cycles of 30 s melting at 951C, 30 s annealing at 601C, 1 min extension at 681C) using the primers listed below:
PCRs were performed using the Taq PCRx polymerase kit from Invitrogen for GC-rich templates. PCR products were resolved in 1% agarose gels and visualised by ethidium bromide staining. The intensity of the PCR products was determined using the GeneTools software from Syngene. 
Transactivation assays
RT-PCR
Total RNA was isolated from cells grown in culture dishes using the RNeasy s kit from Qiagen. cDNA was obtained using the SuperScriptt First-Strand Synthesis System (Invitrogen) following the manufacturer's instructions. PCR reactions of ASPP1, ASPP2 and GAPDH cDNA (25 cycles of 30 s melting at 951C, 30 s annealing at 601C, 30 s extension at 721C) were performed using the primers listed below: 
